Freebies to doctors illegal: ITAT disallows Rs 1 crore business promotion expenses by Mankind Pharma on gift cards

Published On 2022-11-10 13:00 GMT   |   Update On 2022-12-08 07:19 GMT

Denying relief to drugmajor Mankind Pharma Ltd., the Income Tax Appellate Tribunal (ITAT), Delhi has rejected its plea with respect to the disallowance of sale promotion expenses of more than Rs 1 crore to doctors by way of gift cards noting that freebies given to doctors are illegal and does not fall under the head "Business Promotion Expenses".The bench comprising Anil Chaturvedi and...

Login or Register to read the full article

Denying relief to drugmajor Mankind Pharma Ltd., the Income Tax Appellate Tribunal (ITAT), Delhi has rejected its plea with respect to the disallowance of sale promotion expenses of more than Rs 1 crore to doctors by way of gift cards noting that freebies given to doctors are illegal and does not fall under the head "Business Promotion Expenses".

The bench comprising Anil Chaturvedi and Challa Nagendra Prasad, heard the appeal filed by Mankind Pharma against the order of the Deputy Commissioner of Income Tax. The drug maker submitted that no justification was given by the department in denying the sales promotion expenses incurred by the drug maker (assessee) in the form of freebies given to doctors.

For more details, check out the link given below:

Freebies To Doctors Illegal: ITAT Disallows Rs 1 Crore Business Promotion Expenses By Mankind Pharma On Gift Cards

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News